ZyVersa Therapeutics (ZVSA) said Tuesday that recently published data show inflammasome inhibition may protect pancreatic islet beta cells and reduce progression from obesity to insulin resistance and type 2 diabetes.
ZyVersa's Inflammasome ASC Inhibitor IC 100 aims to reduce obesity-related inflammation by inhibiting inflammasome adaptor protein ASC, the company said.
"This data supports the potential of Inflammasome ASC Inhibitor IC 100, as a key component of obesity care when added to incretins used for weight loss," the company said, adding that it plans to initiate phase 1 trials of IC 100 in mid-2025.
Shares of ZyVersa rose more than 37% in recent trading.
Price: 2.60, Change: +0.77, Percent Change: +42.02
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。